RxDoctor Payments Data

Tanya Minich

Adult Health · York, PANPI 1649333808

Payments from drug & device makers

$3,538in general payments, 2019–2025

Across 71 payments — averaging $49.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Actelion Pharmaceuticals US, Inc.$210
  • AstraZeneca$132
  • Scpharmaceuticals Inc.$127
  • Bridgebio Pharma, Inc.$121
  • Kestra Medical Technology Services, Inc.$119
  • plus $491 from 14 others

What the payments were for

  • Travel & lodging$84824%
  • Food & beverage$2,61074%
  • Education$802%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,538 in reported general payments places this provider in the 85th percentile of 899 adult health providers in Pennsylvania.

See all adult health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$33,267
Medicare patients
198
Services billed
556

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis20$428,489
EntrestoSacubitril/Valsartan334$323,576
EliquisApixaban213$195,500
JardianceEmpagliflozin155$139,681
FarxigaDapagliflozin Propanediol39$45,718
XareltoRivaroxaban26$29,848
Bumetanide103$5,135
Potassium Chloride131$5,134
Metoprolol Succinate334$4,652
Torsemide148$2,740
Furosemide441$2,298
Spironolactone378$2,237
Eplerenone36$2,100
Carvedilol186$1,553
Atorvastatin Calcium103$1,076

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$37$623,989233 claims
NovartisEntresto$31$323,576334 claims
AstraZenecaFarxiga$132$45,71839 claims
Johnson & JohnsonXarelto$15$29,84826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 899 adult health providers in Pennsylvania.

Other adult health in York

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →